Back to Search
Start Over
Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines
- Source :
- Biomedicine & Pharmacotherapy, Vol 137, Iss, Pp 111330-(2021), Biomedicine & Pharmacotherapy
- Publication Year :
- 2021
- Publisher :
- Elsevier, 2021.
-
Abstract
- Graphical abstract<br />Highlights • Drug repurposing, depicting patented medicines as an effective technique to develop drugs. • Drug repurposing, compared to de novo drug discovery, could shorten the duration and reduce costs. • Remdesivir and Favipiravir, despite having side effects, were more promising drugs for SARS-CoV-2 infection. • Considering the unparalleled morbidity and deaths associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed.<br />Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a causal factor of the coronavirus disease 2019 (COVID-19). Drug repurposing, portraying patented drugs as a successful drug development technique, could shorten the period and minimize costs relative to de novo drug exploration. Recently several drugs have been used as anti-SARS-CoV-2 such as Remdesivir, Favipiravir, Hydroxychloroquine, Azithromycin, Lopinavir/Ritonavir, Nafamostat mesylate and so on. Despite such efforts, there is currently no successful broad-spectrum antiviral countermeasures to combat SARS-CoV-2 or possibly potential CoVs pandemic. Therefore it is desperately important to recognize and test widely efficient, reliable anti-CoV therapies now and in the future. Remdesivir and Favipiravir were more promising despite having side effects; it had prominent efficacy and efficiency while still not yet approved as the official anti-viral drug for SARS CoV-2. In this review, we summarizes the current drug and vaccine discovery status against SARS-CoV-2, predicting that these efforts will help create effective drugs and vaccines for SARS-CoV-2.
- Subjects :
- 0301 basic medicine
Drug
medicine.medical_specialty
COVID-19 Vaccines
media_common.quotation_subject
viruses
Remdesivir
Review
RM1-950
Favipiravir
Antiviral Agents
03 medical and health sciences
0302 clinical medicine
Pandemic
medicine
Humans
Intensive care medicine
skin and connective tissue diseases
media_common
ComputingMethodologies_COMPUTERGRAPHICS
Pharmacology
Vaccines
business.industry
SARS-CoV-2
virus diseases
COVID-19
Hydroxychloroquine
Lopinavir
General Medicine
biochemical phenomena, metabolism, and nutrition
COVID-19 Drug Treatment
respiratory tract diseases
Drug repositioning
030104 developmental biology
Treatment Outcome
Drug development
030220 oncology & carcinogenesis
Ritonavir
Therapeutics. Pharmacology
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 07533322
- Volume :
- 137
- Database :
- OpenAIRE
- Journal :
- Biomedicine & Pharmacotherapy
- Accession number :
- edsair.doi.dedup.....760b28f01fc56eda9ac9f0bb592a9851